Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
PF-06342674 (RN168) in Adults With Type 1 Diabetes
NCT02038764Phase 1Completed
- Sponsor
- Pfizer
- Start
- Jun 2014
- Primary completion
- Sep 2016
- Modality
- Monoclonal Antibodies
- Countries
- 1
01
Overview
Phase 1, randomised, double-blind trial in type 1 diabetes mellitus (T1D) comparing Placebo with PF-06342674 (2 arms). Primary endpoints: Number of Participants With Dose Limiting or Intolerable Treatment Related Adverse Events, Number of Participants With All-Causality Treatment Emergent Adverse Events (TEAEs) and 7 more. Started Jun 2014; status: completed.
02
Drugs
crebankitug
03
Conditions
type 1 diabetes mellitus (T1D)
Beyond the preview
Go deeper on NCT02038764.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02038764.